WattjesMPRoviraAMillerDH. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
2.
WangCBeadnallHNHattonSN. Automated brain volumetrics in multiple sclerosis: A step closer to clinical application. J Neurol Neurosurg Psychiatry. Epub ahead of print 12April2016. DOI: 10.1136/jnnp-2015-312304.
3.
JacobsenCHagemeierJMyhrKM. Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. J Neurol Neurosurg Psychiatry2014; 85(10): 1109–1115.
SormaniMPArnoldDLDe StefanoN. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75(1): 43–49.
6.
PichlerAKhalilMLangkammerC. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice. Mult Scler2016; 22(3): 340–346.
7.
De StefanoNStromilloMLGiorgioA. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry2016; 87(1): 93–99.
8.
NakamuraKBrownRANarayananS.; Alzheimer’s Disease Neuroimaging Initiative. Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. Neuroimage2015; 118: 126–132.
9.
AzevedoCJPelletierD. Whole-brain atrophy: Ready for implementation into clinical decision-making in multiple sclerosis?Curr Opin Neurol. Epub ahead of print 8April2016. DOI: 10.1097/WCO.0000000000000322.
10.
KapposLDe StefanoNFreedmanMS. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016; 22: 1297–1305.
